Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ranolazine
Drug ID BADD_D01915
Description Chronic angina is a common cardiovascular condition affecting millions worldwide and causes significant disability while interfering with daily activities.[A189234] Ranolazine is a well-tolerated piperazine derivative used for the management of this condition, offering relief from uncomfortable and debilitating symptoms.[L3580] With a mechanism of action different from drugs used to treat the same condition, ranolazine is a promising anti-anginal therapy. It was originally approved by the FDA in 2006.[L5440]
Indications and Usage Ranolazine is indicated for the treatment of chronic angina. It can be used alone or in conjunction with nitrates, beta-blockers, angiotensin receptor blockers, anti-platelet drugs, calcium channel blockers, lipid-lowering drugs, and ACE inhibitors.[L3580] Ranolazine has also been used off-label for the treatment of certain arrhythmias, including ventricular tachycardia, however, this use is not strongly supported by scientific evidence.[A174940] Ranolazine has also been studied for the treatment of acute coronary syndrome, microvascular coronary dysfunction, arrhythmia, and glycemic control, which are not yet approved indications.[A174898,L3580]
Marketing Status approved; investigational
ATC Code C01EB18
DrugBank ID DB00243
KEGG ID D05700
MeSH ID D000069458
PubChem ID 56959
TTD Drug ID D03HYQ
NDC Product Code 50370-0019; 61958-1004; 69367-294; 70625-207; 71610-518; 59651-009; 64552-4024; 67651-0224; 68180-355; 70756-703; 15308-0718; 29300-296; 29300-297; 50228-424; 68180-354; 69367-293; 70771-1500; 63304-017; 68462-319; 69097-221; 72319-021; 40006-043; 42765-048; 73680-0012; 27241-126; 42385-964; 50268-722; 50268-723; 59651-010; 63304-018; 65162-379; 67877-525; 69097-222; 72578-065; 53747-042; 65862-981; 27241-125; 66039-943; 67835-0011; 42571-324; 61958-1003; 63552-142; 72640-001; 31722-668; 31722-669; 43353-880; 47335-624; 68462-320; 70771-1499; 71205-867; 72319-022; 47621-304; 51604-1154; 62512-0076; 67651-0258; 42291-774; 42385-963; 42571-325; 47335-625; 65162-376; 71205-868; 72578-064; 48087-0082; 63552-143; 42291-773; 50228-423; 60687-549; 67877-526; 70625-206; 70756-704; 11014-0108; 48087-0106; 49711-1518; 64220-213; 65372-1190; 70966-0008; 45963-418; 45963-419
UNII A6IEZ5M406
Synonyms Ranolazine | N-(2,6-dimethylphenyl)-4-(2-hydroxy-3-(2-methoxyphenoxy)propyl)-1-piperazineacetamide | Renolazine | Ranolazine Hydrochloride | Hydrochloride, Ranolazine | Ranolazine Dihydrochloride | Dihydrochloride, Ranolazine | Ranolazine HCl | HCl, Ranolazine | Ranexa | RS 43285-193 | RS 43285 193 | RS 43285193 | RS 43285 | 43285, RS | RS-43285 | RS43285
Chemical Information
Molecular Formula C24H33N3O4
CAS Registry Number 95635-55-5
SMILES CC1=C(C(=CC=C1)C)NC(=O)CN2CCN(CC2)CC(COC3=CC=CC=C3OC)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Rash23.03.13.0010.015761%Not Available
Renal failure20.01.03.0050.002191%Not Available
Respiratory disorder22.02.07.0020.000768%Not Available
Respiratory failure22.02.06.002; 14.01.04.0030.001138%
Retching07.01.07.0020.000427%Not Available
Shock24.06.02.002--Not Available
Skin disorder23.03.03.007--Not Available
Sleep apnoea syndrome19.02.05.002; 17.15.05.001; 22.02.01.0130.000768%
Somnolence19.02.05.003; 17.02.04.006--
Speech disorder22.12.03.027; 19.19.02.002; 17.02.08.0030.001110%Not Available
Stress19.06.02.0040.000569%Not Available
Supraventricular tachycardia02.03.03.0120.000626%
Swelling face08.01.03.100; 23.04.01.018; 10.01.05.0180.001252%Not Available
Swollen tongue23.04.01.014; 10.01.05.015; 07.14.02.0030.001053%Not Available
Syncope24.06.02.012; 02.11.04.015; 17.02.04.0080.006202%
Tachycardia02.03.02.0070.001536%Not Available
Therapeutic response unexpected08.06.01.0010.007055%Not Available
Throat tightness22.12.03.031; 19.01.02.0050.000967%Not Available
Thrombocytopenia01.08.01.002--Not Available
Thrombocytosis01.08.02.001--Not Available
Tinnitus17.04.07.004; 04.04.01.0020.003044%
Torsade de pointes02.03.04.0050.001138%Not Available
Transient ischaemic attack24.04.06.005; 17.08.04.0010.000427%
Tremor17.01.06.0020.013855%
Urethral disorder20.07.01.002--Not Available
Urinary retention20.02.02.0110.001138%
Urinary tract disorder20.08.01.001--Not Available
Urticaria23.04.02.001; 10.01.06.001--
Vasodilatation24.03.02.003; 23.06.05.0060.000284%Not Available
Ventricular arrhythmia02.03.04.0060.000427%
The 6th Page    First    Pre   6 7 8    Next   Last    Total 8 Pages